Simplex Trading’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-86
Closed 10235
2023
Q1
$0 Buy
+86
New +$397 ﹤0.01% 10445
2022
Q4
Sell
-9
Closed -$46 10775
2022
Q3
$0 Buy
+9
New +$149 ﹤0.01% 11150
2022
Q2
Sell
-266
Closed -$6.24K 11413
2022
Q1
$9K Sell
266
-150
-36% -$5.19K ﹤0.01% 9005
2021
Q4
$23K Buy
416
+171
+70% +$11.5K ﹤0.01% 8227
2021
Q3
$23K Hold
245
﹤0.01% 8333
2021
Q2
$23K Sell
245
-573
-70% -$63.3K ﹤0.01% 8480
2021
Q1
$120K Buy
818
+707
+637% +$128K ﹤0.01% 5485
2020
Q4
$15K Buy
+111
New +$18K ﹤0.01% 7175
2018
Q2
Sell
-12
Closed -$1.05K 8015
2018
Q1
$1K Buy
12
+6
+100% +$892 ﹤0.01% 5854
2017
Q4
$4K Buy
6
+3
+100% +$1.16K ﹤0.01% 4773
2017
Q3
$0 Buy
+3
New +$819 ﹤0.01% 6823
2017
Q2
Sell
-6
Closed -$1.61K 6955
2017
Q1
$2K Buy
6
+1
+20% +$463 ﹤0.01% 5393
2016
Q4
$2K Hold
5
﹤0.01% 5162
2016
Q3
$5K Sell
5
-11
-69% -$11.9K ﹤0.01% 4346
2016
Q2
$17K Buy
+16
New +$20.1K ﹤0.01% 3063
2016
Q1
Sell
-14
Closed -$19.9K 6409
2015
Q4
$34K Sell
14
-27
-66% -$41.4K ﹤0.01% 2253
2015
Q3
$45K Buy
+41
New +$47.5K ﹤0.01% 2080
2015
Q2
Sell
-1
Closed -$1.08K 6004
2015
Q1
$0 Buy
+1
New +$3.3K ﹤0.01% 5753

Other funds holding NBSE

Simplex Trading's NBSE Position: Q2 2023 in Review

Simplex Trading sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 86 shares.

Simplex Trading first reported a position in NBSE in Q1 2015 and held it in 18 quarters. The position peaked at $120K in Q1 2021. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

  • Simplex Trading reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Simplex Trading sold 86 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023.
  • Simplex Trading first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 18 quarters.
  • Simplex Trading's NeuBase Therapeutics, Inc. Common Stock position peaked at $120K in Q1 2021.
  • 27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.